Clinical trial
There Is No Place Like Home- A Pragmatic Effectiveness Trial of Technology-Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
NCT05038254 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- There Is No Place Like Home- A Pragmatic Effectiveness Trial of Technology-Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- May 12, 2021
- Completion date
- January 31, 2028
- Enrollment
- 750 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iv esophageal adenocarcinoma ajcc v8, clinical stage iv esophageal squamous cell carcinoma ajcc v8, clinical stage iv gastric cancer ajcc v8, clinical stage iva esophageal adenocarcinoma ajcc v8, clinical stage iva esophageal squamous cell carcinoma ajcc v8, clinical stage iva gastric cancer ajcc v8, clinical stage ivb esophageal adenocarcinoma ajcc v8, clinical stage ivb esophageal squamous cell carcinoma ajcc v8, clinical stage ivb gastric cancer ajcc v8, metastatic colon carcinoma, metastatic esophageal carcinoma, metastatic gastric carcinoma, metastatic liver carcinoma, metastatic malignant digestive system neoplasm, metastatic malignant small intestinal neoplasm, metastatic malignant thoracic neoplasm, metastatic pancreatic carcinoma, metastatic rectal carcinoma, pathologic stage iv esophageal adenocarcinoma ajcc v8, pathologic stage iv esophageal squamous cell carcinoma ajcc v8, pathologic stage iv gastric cancer ajcc v8, pathologic stage iva esophageal adenocarcinoma ajcc v8, pathologic stage iva esophageal squamous cell carcinoma ajcc v8, pathologic stage ivb esophageal adenocarcinoma ajcc v8, pathologic stage ivb esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iv esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iv gastric cancer ajcc v8, postneoadjuvant therapy stage iva esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage ivb esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb esophageal squamous cell carcinoma ajcc v8, stage iv colon cancer ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iv pancreatic cancer ajcc v8, stage iv rectal cancer ajcc v8, stage iv small intestinal, esophageal, colorectal, mesenteric, and peritoneal gastrointestinal stromal tumor ajcc v8, stage iva colon cancer ajcc v8, stage iva hepatocellular carcinoma ajcc v8, stage iva rectal cancer ajcc v8, stage ivb colon cancer ajcc v8, stage ivb hepatocellular carcinoma ajcc v8, stage ivb rectal cancer ajcc v8, stage ivc colon cancer ajcc v8, stage ivc rectal cancer ajcc v8